Physician profile
Kevin E Stone
NPI 1730178443
$6,154.87
in general payments reported to CMS, 2019-2025
27 companies · $896 in 2025
The $896 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $198 · 2021: $397 · 2022: $1,133 · 2023: $449 · 2024: $2,120 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Travel and Lodging: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.60 |
| Travel and Lodging | $1,081.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,271.08 | 2024 | Saphnelo |
| Abbvie INC. | $1,139.99 | 2021-2025 | Rinvoq, Humira, Skyrizi |
| Novartis Pharmaceuticals Corporation | $867.12 | 2019-2025 | |
| Janssen Biotech, INC. | $460.07 | 2019-2025 | Tremfya |
| Amgen INC. | $376.00 | 2019-2024 | Otezla, Amjevita, Avsola |
| Glaxosmithkline, LLC. | $316.46 | 2019-2025 | Benlysta, Nucala |
| Genzyme Corporation | $265.96 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $214.29 | 2020-2025 | Orencia |
| Ucb, INC. | $212.32 | 2022-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $152.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $132.04 | 2021-2024 | Saphnelo |
| Pfizer INC. | $120.66 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $115.77 | 2021-2024 | Acthar |
| Genentech USA, INC. | $63.62 | 2022-2025 | Gazyva |
| Sanofi-Aventis U.S. LLC | $59.99 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $51.15 | 2019-2022 | |
| Horizon Therapeutics Plc | $49.07 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.59 | 2023-2024 | Ofev |
| Lilly USA, LLC | $45.23 | 2019 | |
| Janssen Scientific Affairs, LLC | $28.74 | 2024 | Tremfya |
| Kiniksa Pharmaceuticals, Ltd. | $27.67 | 2021 | |
| Mallinckrodt Enterprises LLC | $26.93 | 2019 | |
| Octapharma USA, INC. | $26.41 | 2023 | Octagam Immune Globulin (Human) |
| Medexus Pharma, INC. | $25.55 | 2019 | |
| Alvogen INC | $23.96 | 2025 | Teriparatide |
| Celgene Corporation | $20.83 | 2019 | |
| Sobi, INC | $13.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.